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This study aimed to investigate the short-term effects of Highly Active Antiretroviral Therapy (HAART) 
(stavudine, lamivudine and nevirapine) on serum lipids of HIV-1 positive subjects in Benin City, Nigeria. 
Test group 1 (n=78) and test group 2 (n= 71) comprised HIV- 1 seropositive individuals on HAART for a 
period of one to three months; and five to six months respectively. Fifty five newly diagnosed HIV-1 
positive subjects naïve to HAART served as control group 1 and sixty apparently healthy HIV-1 
seronegative individuals served as control group 2. The blood samples obtained were analyzed for total 
cholesterol, triglycerides, low-density lipoprotein and high-density lipoprotein using standard enzymatic 
methods. Total cholesterol of test group 2 (214.0±6.43mg/dL) was not significantly different from Test 
group 1 (202.4±5.09mg/dL), both were however significantly higher than control group 1 
(159.3±5.09mg/dL) and control group 2 (101.6±3.76 mg/dL). Triglyceride concentration of test group 2 
(106.6+11.95mg/dL) was not significantly different from test group 1 (135.8+9.88mg/dL), but were 
significantly different from control groups 1 and 2 (125.1+3.35mg/dL and 104.6+3.08mg/dL) 
respectively. Dyslipidemia could set in from 1 to 6 months of HAART usage in HIV-1 Positive subjects 
hence serum lipids should be monitored as early as one month of HAART commencement. 
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INTRODUCTION 
One of the reasonable goals for HIV 
chemotherapy (HAART) is to get the most 
effective drugs with minimal or negligible side 
effects in the long run. However, the long term 
survival of the treated patients have revealed 
several metabolic complications such as 
lipodystrophy, bone mineral depletion, liver 
failure, lactic acidosis, among others. Elevated 
serum triglycerides, total cholesterol, very low - 
density lipoprotein (VLDL) cholesterol, and low 
density lipoprotein (LDL) cholesterol have been 
reported in the literature from areas where 
experience with antiretroviral drugs has built 
up. It was reported in the study conducted by 
Kubeyinje and Imarhiagbe (2005) that three 
cases out of eleven followed up on 
antiretroviral drugs for a period of 6 months had 
a steady rise in serum triglyceride level, among 
other parameters.  
 
Until recently, the use of antiretroviral drugs in 
Nigeria on a wide scale was a rarity owing 
largely to prohibitive cost, and so experience 
with its use was limited. HAARTs are now 
highly subsidized or in some cases free in 
Nigeria. Study of this nature is important 
among different indigenous populations and 
communities, to help ascertain effects of these 
agents on lipid metabolism and on the liver as 
an important metabolic organ (Aggarwal et al., 
1996).  
 
Therefore, understanding the establishment 
and progress of HAART induced toxicity with 
short term usage by HIV-1 subjects in Nigeria 
would be of important research interest. Highly 
Active Antiretroviral Therapy (HAART) is 
composed of multiple antiretroviral drugs, 
which usually includes one nucleoside analog 
(Deoxyribonucleic Acid chain terminator), one 
protease inhibitor and either a second 
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nucleoside analog or a non-nucleoside reverse 
transcription inhibitor (NNRTT) (Aggarwal et al., 
1996; Aggarwal and Olivero, 1997). 
 
Several advances have been made in the 
management and treatment of HIV/AIDS 
infection. Of particular note is the use of 
HAART, which has significantly decreased the 
morbidity and mortality caused by the infection 
(Stacpoole, 1993; Smit et al., 2003; Kubeyinje 
and Imarhiagbe, 2005; Pol et al., 2011). 
However, the long term survival of the treated 
patients have revealed several metabolic 
complications such as lipodystrophy (condition 
resulting in loss of fat tissues from part or all of 
the body), bone mineral depletion, liver failure, 
lactic acidosis, among others (Aggarwal et al., 
1996). Also, among a cohort of seventy four 
(74) HIV positive persons treated with HAART, 
there was evidence of Lipodystrophy (Aggarwal 
and Olivero, 1997. Elevated serum 
triglycerides, total cholesterol, very low-density 
lipoprotein (VLDL) cholesterol, and low-density 
lipoprotein (LDL) cholesterol have been 
reported in the literature from areas involved in 
therapeutic trials (Aggarwal et al., 1996; 
Aggarwal and Olivero, 1997). 
 
Based on cultural and environmental 
differences, the situation (HAART and its 
effects) in our local environments needs to be 
known in greater dimensions, and then 
compared with data and findings from foreign 
studies. This is very important especially for the 
HIV positive Nigerians who have shown serious 
compliance with the antiretroviral therapies. 
Beside the aim of establishing the long and 
short term effects of HAART on liver enzymes, 
this study also seeks to direct research 
attention on how to solve the problems of 
effects the drugs in order to minimize their side 
effects for the betterment of people living with 
HIV/AIDS in Nigeria, who of course still have 
full right to life. 
MATERIALS AND METHODS 
The Subjects (Test Groups) 
Two Test Groups were used: Test Group One 
and Test Group Two. 
Test Group One: HIV-1 Positive Individuals on 
HAART for 1-3 Months A total of seventy eight 
(78) blood samples from HIV-1 positive patients 
(49 females and 29 males) who were on 
HAART for a duration of 1-3 months were 
analyzed for serum lipids: total cholesterol, 
triglycerides, low density lipoproteins (LDL), 
and high density lipoproteins (HDL). 
 
Test Group Two: HIV-1 Positive Individuals on 
HAART for 5-6 Months A total of seventy one 
(71) blood samples from HIV-1 positive patients 
(30 males and 41 females) who were on 
HAART for a duration of 5 -6 months were 
analyzed for Serum lipids: total cholesterol, 
triglycerides, low density lipoproteins (LDL), 
and high density lipoproteins(HDL). 
 
Permission for Sample Collection/Inclusion 
Criteria 
The above groups of patients were known HIV-
1 sero-positive patients attending a 
Government owned health facility in Edo State 
for routine laboratory testing and for assess to 
antiretroviral therapies. Care was taken to 
ensure that patients reasonably complying with 
drug usage were selected for the work. 
Approval of ethical committee with permission 
to obtain samples was sought and obtained 
from the head of the laboratory department on 
behalf of hospital management. All samples 
were obtained in line with the Ethical Principles 
for Medical Research Involving Human 
Subjects by World Medical Association 
Declaration, Helsinki, 1994 and 2000. 
 
The Control Groups 
Two control groups were used:  Control group 
one and Control group two. 
 
Control Group One: A total of fifty (50) blood 
samples were obtained from individuals newly 
diagnosed of HIV-1 (both first timers and those 
already attending counseling sessions before 
commencement of antiretroviral therapies). 
Subjects of this group were apparently healthy 
and were, for one reason or the other attending 
clinic in a missionary hospital and the 
aforementioned source, both in Benin City. 
They were however, screened using Determine 
HIV 1/2 diagnostic strips; and the results 
showed positive. 




Control Group Two: A total of sixty one (61) 
samples were obtained from apparently healthy 
volunteers chosen from random population. 
They included friends, co-workers, students, 
and fuel attendants. They were screened using 
Determine Test Kits and only the HIV sero-
negative subjects were included in the research 
work. In all the control subjects, liver enzymes 
activities and lipid profile were equally 
determined. 
 
The Antiretroviral Drugs: Three different 
antiretroviral drugs made up of Nucleoside 
Reverse Transcriptase Inhibitors 
(stavudine/lamivudine) and Non-nucleoside 
Reverse Transcriptase Inhibitors (Nevirapine) 
constituted the HAART administered to the test 
group individuals in the centre where samples 
were obtained. 
 
Sample Collection and Storage: Venous 
blood samples were obtained in plain 
(anticoagulant-free) specimen bottles using 
acceptable phlebotomy techniques. 
The blood samples were allowed to clot, 
centrifuged at 3000 revolution per minute for 3 
minutes, sera were collected and analysed 
immediately for the research parameters. 
Where this was not possible, the samples were 
stored frozen until required. Frozen samples 
were thawed and brought to room temperature 
before being analysed. All samples for the 
different groups were properly labeled to avoid 
mix-up and were handled using safety gloves 
and protective lab clothing. The samples were 
immediately discarded for incineration after 
analysis. Sodium hypochlorite (10%) solution 
was used to disinfect working areas after 
analysis. It was ensured that all handling and 
analysis of samples took place in approved 
working areas only. 
 
Estimation of Serum Lipid Profile 
The lipid profile analysis of the samples was 




The single factor ANOVA both parametric and 
non-parametric was used to determine 
significant differences in the enzyme activities 
and lipid levels in the two durations of HAART 
usage and in the two control groups. Where a 
significant difference (P<0.05) was detected, 
the Duncan Multiple Range Test was used to 
locate the source of difference. All statistical 
analyses including the descriptive statistics 





Table 1: Lipid Profile of Test and Control Subjects 
  
Test group 2 Test group 1 
Control Group 
1 No HAART: 





HAART: HIV positive No HAART: P-value 
    1-3 months   HIV negative   
Total 
Cholesterol 
214.0A + 6.43 202.4A + 5.09 159.3 B +5.09 101.6 C + 3.76 P<0.001 
     
Significant 
Triglyceride 106.6 A + 11.95 135.8 A +9.88 125.1 B +3.35 104.6 C + 3.08 P<0.005 
     
Significant 
HDL 48.7 A + 3.95 42.2 B + 3.21 39.6 B + 3.10 25.1 C + 0.77 P<0.001 
     
Significant 
LDL 130.3 A + 6.36 115.7 B +4.73 106.5 B +3.12 115.3 B + 1.54 P<0.005 
          Significant 
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Total cholesterol concentration of Test 
group 2 (214 ± 6.43 mg/dL) was higher than 
the concentration obtained for Test group 1 
(202 ±5.09 mg/dL), but the difference was not 
significant. These values were higher than 
values obtained for both control groups and 
the differences were highly statistically 
significant (P< 0.01). In the control groups, the 
total cholesterol concentration was higher in 
the control groups 1; HIV positive NO HAART; 
(159.3 ± 5.09 mg/dL) than in control group 2, 
(101.0 ± 3.76 mg/dL) and the difference was 
highly significant (P<0.001). Table 1 also 
shows triglycerides concentrations of test and 
control groups. Pattern similar to the above (for 
cholesterol) was observed for triglyceride, 
however, differences observed were significant 
(P<0.05). 
 
As shown in table 1, HDL cholesterol 
concentration for test groups 2 (48.7 ± 3 .95 
mg/dL) was higher than concentration of test 
group 1 (42.2 ±3.21 mg/dL) and the difference 
was highly significant (P<0.001). There was 
however no significant difference between 
concentration of test group 1 and control group 
1(39.6±3.10 mg/dL). Comparison of HDL 
concentration between control groups showed 
that values obtained for control group 1 was 
higher than control group 2 (25.1 ± 0.077 
mg/dL) and the difference was highly 
significant (P<001). Difference in LDL 
concentration between test group 2 (130.3 ± 
6.36 mg/dL) and test group 1 (115.7 ± 4.72 
mg/dL) was significant (p<0.05) though LDL 
concentration of test group was higher. It was 
however observed that there was no significant 
difference between LDL values obtained for 




Table 2: Prevalence of Hypercholesterolaemia in the Different Subjects 











Desirable (<200mg/dL) 44.90% 36.60% 100% 90.20% 
Borderline high (200-239 mg/dL) 35.90% 32.40% 0.00% 8.20% 
High: >240mg/dL 19.20% 31.00% 0.00% 1.60% 
 
 
Table 3: Prevalence of Hypertriglyceridaemia in the Different Subjects 
Triglyceride 
(mg/dL) 








Normal: 66.70% 60.60% 98.00% 80.30% 
<150         
Borderline 15.40% 8.40% 2.00% 19.70% 
High:         
150-199         
High: 17.90% 31.00% 0.00% 0.00% 
200-499         
Very High: 0.00% 0.00% 0.00% 0.00% 
>500         
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Table 2 shows the prevalence of 
hypercholesterolemia in different groups of 
subjects under study. Control group 1 showed 
no incidence of either high or border line high 
cholesterol values. However, control group 2 
(HIV negative, No HAART) 8.2% and 1.6% of 
subjects had border line high and high 
cholesterol values respectively. In the test 
groups the percentage of borderline high 
cholesterol level for test group 1 (35.9%) was 
greater than the percentage of group 2 
(32.4%). However, high cholesterol (> 
240mg/dl) was more prevalent in test group 
2(31.0%) than in test group 1 (19.2%). 
Summarily, values in table 15 shows that 
hypercholesterolemia (cholesterol >200mg/dl) 
was more prevalent in test groups (HAART 
usage) than in control groups (no HAART). 
 
Table 3 shows percentage of 
Hypertriglyceridaemia in test and control 
groups. Cases of Hypertriglyceridaemia 
(triglyceride greater than 150mg/dl) were 
observed in test group 1 (15.4% and 17.9%) 
for border line high and high respectively; and 
8.4% (Border line high) and 31.0% (high) for 
test group 2. Incidence of high 
Hypertriglyceridaemia in test group 2 (31%) 
was greater than 17.9% obtained for test group 
1. There was no case of very high triglyceride 
(> 500mg/dl) in both test groups and control 
groups. 
 
Table 4: Serum Lipids Concentration for Male and Female of Test Group 2 
Parameter (mg/dL) 





Total cholesterol 212.2 ±9.21 215.4 ±8.96 P>0.05 
Triglycerides 173.7± 20.17 151.0 ± 14.54 P>0.05 
 
Table 5: Mean Serum Lipids Concentration for Male and Female of Test Group 1 




Total cholesterol 186.6 ±9.33 211.7 ± 5.58 P<0.05 
Triglycerides 163.2+20.29 119.5 + 9.6 P<0.05 
 
Table 6: Mean Serum Lipid Concentration for Male and Female of Control Group 1 
Parameter (mg/dL) 





Total cholesterol 98.85 ± 5.33 104.5 ±5.35 P>0.05 
Triglycerides 102.96± 4.77 106.33 ± 3.88 P>0.05 
 
Table 7: Mean Serum Lipid Concentration for Male and Female of Control Group 2 
Parameter  
(mg/dL) 




Total cholesterol 162.5 ±8.66 156.5 ±5.8 P>0.05 
Triglycerides 123.0 ±5.17 127.0 ±4.39 P>0.05 
 
DISCUSSION 
It would be clinically valuable for HIV 
Chemotherapy to have minimal of negligible 
side effects with long-term use, alongside its 
effectiveness. The possible lipid derangement 
effects of the HAART used by participants in 
this study is of interest. The combination of the 
three different antiretroviral drugs made up of 
Nucleoside reverse transcriptase inhibitors 
(Stavudine and Lamivudine) and non-
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nucleoside reverse transcriptase inhibitors 
(nevirapine) used by participants in test groups 
1 and 2 may be associated with has the 
considerable difference in their lipid profile 
indices, which obviously were higher compared 
with the control groups. 
 
It could therefore be implied that the 
observed differences in serum lipid levels, 
(cholesterol for instance) in test groups (those 
with HAART usage) may be attributed to the 
influence of HAART on lipids metabolism. In 
this study, this comparatively higher levels in 
serum lipids of participants with HAART 
usage is being further supported by the 
percentage prevalence of 
hypercholesterolemia in test subjects which 
were significantly higher than prevalence 
seen in control subjects.  
 
The non-usage of HAART by control 
subjects justifies the zero incidence and very 
low incidence of hypercholesterolemia in 
control group 1 and 2 respectively as indicated 
in tables 2 and 3. Also, 8.4% borderline high 
and 31.0% high Hypertriglyceridaemia were 
seen in test group 2. This incidence of high 
Hypertriglyceridaemia (31% of subjects) in test 
group 2 was greater than the 17.9% obtained 
for test group 1. It could be implied that as the 
duration of HAART usage increases, the 
tendency for serious derangement in lipids like 
triglycerides is established. Changes in lipid 
levels (triglycerides) may be mild in short 
durations of HAART usage and this may have 
accounted for reason why there was no case 
of very high triglyceride (values > 500mg/dl) in 
the test groups, since HAART was used for 
short durations. 
 
HAART usage has been linked to 
such metabolic disorders as dyslipidaemia, 
lipodystrophy, hyperinsulinaemia, 
hypoglycaemia, insulin resistance and lactic 
acidosis among others. Nucleoside analogue 
antiretroviral agents (NRTIs) exert their effect 
on HIV by inhibiting reverse transcriptase. 
These agents also inhibit mitochondrial DNA 
(mtDNA) polymerase in cell culture (Aggarwal 
et al., 1996; Aggarwal and Olivero, 1997); Pol 
et al., 2011). Inhibition of mtDNA can lead to a 
variety of metabolic abnormalities which 
include derangement in pyruvate metabolism 
and ultimately disorders in lipid profiles. Insulin 
resistance and hyperinsulinaemia are 
important metabolic disorders in HAART 
usage that lead to increased serum lipids. 
Insulin resistance in fat cells results in 
hydrolysis of stored triglycerides, which 
elevate free fatty acids in the blood plasma4. 
Subjects who are insulin resistant typically 
have an imbalance in their blood lipids ("blood 
fat). They have an increased level of 
triglycerides and a decreased level of HDL I 
good) cholesterol. Imbalances in triglycerides 
and HDL cholesterol increase the risk for heart 
disease5. Elevated serum triglycerides, total 
cholesterol and very low - density 
lipoproprotein (VLDL) cholesterol, and low 
density lipoprotein (LDL) cholesterol have 
been reported in literature from areas where 
experience with antiretroviral drugs has built 
up (Kubeyinje and Imarhiagbe, 2005). It was 
reported that LDL cholesterol is one of the lipid 
parameters seriously affected by long duration 
HAART usage. Also, Riddler et al (2003) 
observed that before treatment, infection 
resulted in substantial decreases in serum 
total cholesterol, HDL and LDL cholesterol 
levels and that subsequent HAART initiation 
was associated increases in total cholesterol 
and LDL - cholesterol, but little change in HDL 
cholesterol. 
 
In this study, as indicated in table 1, 
difference in LDL concentration between test 
group 2 and test group 1 was significant; test 
group 2 was significantly higher than test 
group 1. When LDL concentration of test group 
1 was compared with the control groups, 
though higher, the differences were not 
significant. Rising levels of LDL cholesterol in 
HIV subjects with HAART constitutes 
additional risk factor for heart related diseases 
like atherosclerosis and heart attack. The 
HAART group of 5-6 months (Test group 2) 
had higher HDL concentration than the 1-3 
month HAART subjects (test group 1). This 
observation significantly varies with report of 
most studies which show decreasing levels of 
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the beneficial cholesterol (HDL). HDL 
cholesterol has heart-protecting effect. The 
risk of HAART usage would have been 
significantly reduced if it were associated with 
rising levels of serum HDL cholesterol. 
 
The values obtained in the study for 
total cholesterol, triglyceride and LDL 
cholesterol indicates that mild elevations are 
associated with HAART usage even for 
durations as short as 1 -3 months and 5 - 
6months. This is in line with the observations 
of Kubeyinge and Imarhiagbe in a locally 
conducted study (Kubeyinje and Imarhiagbe, 
2005), who reported that 3 cases out of eleven 
followed up on antiretroviral drugs for a period 
of 6months had a steady rise in serum 
triglycerides among other parameters. 
 
Mitochondrial dysfunction which 
ultimately leads to gluconeogenesis, 
hyperinsulinaemia, insulin resistance, 
increased fat synthesis as well as, fatty liver 
development and weight gain are biochemical 
abnormalities that can directly alter liver 
enzymes and lipid profiles in HAART using 
HIV subjects. Occurrence of mitochondrial 
dysfunction is listed as part of the suggested 
mechanisms by which HAARTs cause 
cytotoxicities, (Stacpoole, et al., 1993; 
Aggarwal et al., 1997;  Stacpoole et al., 1997; 
Ammassari et al., 2001). In mitochondrial 
toxicity, the mitochondria are damaged and 
lactic acid is not broken down. This can cause 
levels of lactic acid to become elevated. If this 
level becomes too high, a rare serious 
condition called lactic acidosis can occur.  
 
Lactic acidosis can result in liver 
problems, including a buildup of fat in and 
around the liver and liver inflammation (Parker 
and Cheng, 1994; Lewis et al., 1996; Aggarwal 
and Olivero, 1997; Ammassari et al., 2001). 
Suggested mechanisms and manifestations of 
mitochondrial dysfunction with HAART usage 
has been reported. The nucleoside analogue 
antiretroviral agents (stavudine and lamivudine 
used in this study) exert their effect on HIV by 
inhibiting reverse transcriptase. These agents 
also inhibit mitochondrial DNA (mtDNA) 
polymerase in cell culture (Aggarwal and 
Olivero, 1997; Riddler et al., 2001). The NRTIs 
have effect on mtDNA synthesis. 
 
Inhibition of mtDNA can lead to a 
variety of metabolic abnormalities. These are 
largely the result of a derangement in pyruvate 
metabolism. After formation by glycolysis, 
pyruvate is metabolized in the mitochondria by 
pyruvate dehydrogenase (PDH) to acetyl co-
enzyme A (co A). Pyruvate may be reduced to 
lactate by lactate dehydrogenase, and it may 
also be used in gluconeogenesis (Stacpoole 
1993; Stacpoole, 1997). 
 
Inhibition of mtDNA causes a disorder 
of oxidative phosphorylation by making the 
mitochondrial respiratory chain dysfunctional 
and unable to break down acetyl CoA. This 
dysfunction shifts pyruvate metabolism forward 
the other pathways, reduction to lactate and 
gluconeogenesis. The lactate cannot be 
cleared as rapidly as it is being produced, and 
the resultant excess causes acidosis. The 
increase of pyruvate leads to increased 
gluconeogenesis in the liver, resulting in 
secondary diabetes mellitus (Kraise and 
Musher 1997). The gluconeogenesis 
stimulates insulin production. The over 
production of acetyl CoA without utilization in 
the respiratory chain pushes it out of the 
mitochondria to the cytoplasm, where it serves 
as a substrate for fat production. The over 
production of lactate causes lactic acidosis; the 
gluconeogenesis causes secondary diabetes 
mellitus and hyperinsulinaemia. 
Hyperinsulinaemia causes insulin resistance, 
and fat synthesis causes fatty liver and weight 
gain (Aggarwal and Olivero, 1997). Lactic 
acidosis which is as a result of mitochondrial 
toxicity as seen in the above mechanism can 
result to liver problems, including a build-up of 
fat in and around the liver and liver 
inflammation as well as increase fat synthesis 
(Qagish et al., 2000). 
 
CONCLUSION 
This study concludes that though there 
was no extreme cases of lipid derangement 
associated with the duration of HAART usage 
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in the participants studied, the significant 
differences observed in lipid levels between 
study participants (test and control groups) 
show a trend in that direction. Serum lipids 
should therefore be evaluated before 
commencement of HAART and monitored in 
the course of HAART usage, possibly from the 
month of commencement. 
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